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ABSTRACT
GENETIC CHARACTERIZATION OF THE, K2 SEROTYPE CAPSUL.E OF

KLEBSIELLA PNEUMONIAE ATCC 43816 AND THE

DEVELOPME~IT

OF A

BIOLUMINESCENT STRAIN

Jacob Brandon Scott
April 23, 2013

OBJECTIVE: Klebsiella pneumoniae is a Gram-negative enterobacterium that is
a major cause of community-acquired and nosocomial infections. We performed
a genetic characterization of K. pneumoniae strain ATCC 43816, which is a wellstudied strain with a K2 serotype capsular polysaccharide. To provide

thl~

ability

to monitor bacteria within a host, we will develop a bioluminescence stra n of K.

pneumoniae by integrating the lux operon into the chromosome. METHODS: The
ATCC 43816 capsule cluster sequencing was performed by closing gapE, in the
Next Generation Sequencing by long range peR for template and primer
walking. We constructed a bioluminescent K. pneumoniae by using allelit::
exchange strategies and subsequently characterized the bioluminescent strain
JSKP001 in a macrophage infection model. RESULTS: We have sequerced and
annotated the CPS cluster as a 23,804-base pair sequence and identified eight
homologous genes conserved between all serotypes of Klebsiella. Using our

v

bioluminescent strain JSKP001, we demonstrate that K. pneumoniae may enter
a reduced metabolic state within macrophages. CONCLUSION: We havH
successfully sequenced and annotated a K2 serotype CPS cluster with high
homology to other K2 serotypes K. pneumoniae strains. We observed that K.
pneumoniae is internalized by macrophages, but proliferates at a slow rate. We
tested our bioluminescent strain in numerous growth conditions and found that
rich growth media supports higher metabolic activity while the lowest activity was
detected in K. pneumoniae internalized within rnacrophages. This suggeBts that
macrophages may only provide a minor role as an intracellular replicativE! niche
in vivo, but might be a potential niche for chronic persistence in sublethal
infections.
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CHAPTER I
INTRODUCTION
1.1 History
It has been less than 140 years since our understanding of the ability of
bacteria to cause lethal pneumonia was first established from the combined
efforts of Edwin Klebs and Carl Friedlander in the late 19th century [1, 2]. It was
in Friedlander's laboratory where Hans Christian Gram developed the "GI-am
stain" technique to detect bacteria in histological sections of the mammalian lung
[3]. This technique stains bacteria one of two colors: Gram-positive (purple/blue)
and Gram-negative (pink/red), of which Klebsiella pneumoniae was the first
identified as a Gram-negative organism, distinguished from the previousl)'
observed Gram-positive Streptococcus pneumoniae [4].
1.2 Epidemiology
K. pneumoniae subsp_ pneumoniae (K. pneumoniae) is a Gram-negative,
non-motile, encapsulated, rod-shaped bacterial pathogen that is ubiquitollsly
found in nature as well as mucosal surfaces of animals [5]. K. pneumoniae is an
opportunistic pathogen that primarily infects imrnunocompromised individuals
with underlying or pre-existing health conditions such as diabetes mellitus,
alcoholism, and chronic pulmonary obstructions_ As an opportunistic path:>gen,
K. pneumoniae is responsible for causing a wide-range of infections from urinary
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tract infections (UTI's), septicemia, intestinal infections, wound infections and
pneumonia [6, 7]. Furthermore, antibiotic resistant K. pneumoniae is a

si!~nificant

contributor to nosocomial and community-acqUlired infections worldwide 18, 9].

1.2.1 Nosocomial Infections

K. pneumoniae has been described as the 7th most frequently cultured
clinical isolate overall in U.S. hospitals [10] and the 4th overall in European
hospitals [11]. The two most common presentations of K. pneumoniae in
hospitals are in the airway and urinary tract infections, frequently associated with
the use of contaminated medical devices such as endotracheal tubes or
catheters (Frank et aI., 2009; Jones, 2010). Since the 1970's, K. pneumoniae
nosocomial infections in westernized hospitals have become increasingly
associated with resistance to aminoglycoside antibiotics allowing for incmased
persistence within the health care setting [12]. However, in recent years )(
pneumoniae strains have acquired plasmid-based extended-spectrum

13-

lactamases (ESBLs) [13], which convey resistance against newer
cephalosporins. Currently, carbapenem antibiotics (imipenem and meropenem)
are the most effective antibiotics against Gram··negative, respiratory-assc,ciated
infections [14]. Consistent with the ability of K. pneumoniae to acquire antibiotic
resistance, the pathogen has recently developed resistance to carbapenE!m
antibiotics leaving limited treatment options and causing an increase in concern
over the spread of carbapenemases expressing K. pneumoniae (KPC) st-ains
which are associated with mortality rates of bacteremia ranging from 24% to 70%
[15]. Current treatment options for KPC infections include the use of polymyxin
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combination therapies (73% success rate) or tigecycline (71 % success rate) [12].
While K. pneumoniae nosocomial infections are primarily found in western
countries, in developing countries community-acquired K. pneumoniae irfections
are more prevalent [16-18].
1.2.2 Community-Acquired Infections
In Southeast Asia and Africa, K. pneumoniae is among the most
frequently isolated causative agents of community-acquired pneumonia (CAP)
(15.8%). This geographical representation of CAP could be due to differe,nces in
bacterial strains, host defense, or socioeconomic factors (e.g. environmental
sanitation and primary healthcare) [19, 20]. In a worldwide study, 5% of patients
in Taiwan and South Africa received antibiotic treatment prior to hospitalization
compared to 23% of patients in westernized countries [19]. Additionally, '1/5 of
patients admitted to hospitals with community-acquired K. pneumoniae
presented bacteremia and required intensive care with mortality rates raiBing up
to 55% [21-23]. K. pneumoniae CAP infections are associated with alcoh::>lism in
South Africa and Taiwan as 18% of the patients were alcoholics unlike
westernized countries where alcoholism is not prevalent in patients [19].
In Taiwan, the manifestation of soft tissue infection caused by communityacquired K. pneumoniae was originally characterized as a liver abscess cmd the
patients who were diagnosed with this disease had an overall mortality rate of
23% [24, 25]. Liver abscesses associated with K. pneumoniae are associated
with K1 or K2 serotypes and have been predominately found in Southeast Asia
with the infections often complicated with meningitis, which results in a mortality
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rate of 30% to 40% [24,26,27]. This prominence of K. pneumoniae in both
nosocomial and community-acquired infections has highlighted the impo 1ance of
identifying mechanisms of virulence for this pathogen.

1.3 Virulence Factors:
1.3.1 Siderophores
Iron is a critical co-factor for K. pneumoniae virulence in animal models as
it functions as a redox catalyst in proteins participating in oxygen and electron
transport processes [28, 29]. K. pneumoniae secures iron from hosts by
secreting siderophores such as yersiniabactin that competitively take up iron
bound to host proteins [30-34]. More virulent strains of K. pneumoniae have been
found to express three siderophores, yersiniabactin, enterobactin and
salmochelin, suggesting that these three siderophores may playa key role in
enhancing the virulence of the pathogen in an intranasal mouse model pO, 33,
35].

1.3.2.1 Fimbrial Adhesion
The ability of K. pneumoniae to adhere to mucosal and epithelial cell
surfaces is mediated in part through fimbriae adhesions, a key componellt to
colonization and infection [36]. K. pneumoniae possesses 2 types of fimbriae: i)
Type 1 fimbriae which facilitates attachment to bladder epithelium [37, 3f1] and ii)
Type 3 fimbriae which mediates biofilm formation in endothelial cells, as i/IIell as
adhesion to the basement membrane of lung tilssue [39-41].
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1.3.2.2 Biofilm Formation
Fimbriae are required for biofilm formation of K. pneumoniae and facilitate
the colonization of various ecological niches [40]. Biofilm formation

allow~i

K.

pneumoniae to colonize surfaces like catheters in hospitalized patients and has
led to the spread of nosocomial infections [39]. The biofilm is linked to en 1anced
bacterial resistance to antibiotic therapies and host defenses against K.
pneumoniae [42, 43].

1.3.3 Lipopolysaccharide
The lipopolysaccharide (LPS) of K. pneumoniae is a major component of
the outer membrane which consists of lipid A, a core polysaccharide, and the
side chain O-antigen polysaccharide. LPS is critical for K. pneumoniae to resist
complement-mediated killing during infection [44]. The structure of the
oligosaccharide-repeating units of the O-antigen of K. pneumoniae's LPS serves
as a site for attachment of surfactant protein 0, which decreases the adhHsion to
lung epithelial cells [45]. Surfactant protein 0 plays an important role in the
regulation of innate immune responses in the lungs and causes agglutination and
enhanced macrophage-dependent killing of K. pneumoniae [46]. Klebsiella
strains that bind and agglutinate surfactant protein 0 by their mannose-rich 0
antigens are less able to infect the lungs compared to strains expressing
galactose-rich 0 antigens [47]. K. pneumoniae that expresses 0 antigen
recognized by surfactant protein 0 triggers the induction of cytokine respclnse,
which sets the stage for the innate immunity components [47]. The LPS of K.
pneumoniae is considered to be a major virulence factor, which helps the
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bacteria evade host immune responses and promote the persistence of illfection
in various hosts.

1.3.4 Capsular Polysaccharide
The capsular polysaccharide (CPS) of /'(. pneumoniae covers the iJacterial
surface and protects the bacterium from the host's inflammatory respons'3, from
opsonization, and subsequent phagocytosis [48]. K. pneumoniae produces a
large hydrophilic capsule (160nm) consists of repeating subunits of 4 to Ei sugars
(glucose, galactose, mannose, fucose and rhamnose) with numerous
configurations leading to a diverse capsule library of 80 different capsulal·
antigens which has been described for Klebsiella [49].

1.3.4.1 CPS Regulation
The mucoid phenotype found in liver abscess isolates is thought to be
regulated by the rmpA gene [50]. The serotypes K1 and K2 are significantly more
prevalent in strains that cause liver abscess than in the strains causing
bacteremia alone [51]. In the K2 serotype strains, the rmpA has an isoforll
rmp2A gene that has shown to regulate CPS biosynthesis [52]. The rmpA and
rmp2A gene belongs to the UhpA-LuxR family of transcription factors, which also

includes rcsA and rcsB that are also known as regulatory genes for capsule
synthesis [53]. The RscA, RmpA or RmpA2 proteins have all been demonstrated
to interact with the RcsB protein to form a heterodimer in order to bind
specifically to the CPS promoter for transcription initiation [52, 54-56]. Th s
regulation of the CPS by the RscA, RmpA or RmpA2 proteins has been
demonstrated to be associated with temperature as the production of the CPS is
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at maximum levels when bacterial growth rate is low [57]. Since the biosynthesis
of capsule in K. pneumoniae is controlled by a two-component regulatory system
[54, 58], it is likely that multiple accessory factors may be used in order t()
increase the CPS biosynthesis in response to different environmental stimuli [52,
55].
1.3.4.2 Complement Cascade Defense
The CPS of K. pneumoniae resists the nonspecific host defense
mechanism such as the complement cascade, which plays a crucial role in the
early host defense against invading pathogens [59]. In vitro studies have shown
that CPS inhibits the deposit of the C3 complement component onto the
bacteria's surface and reduces the formation of the membrane attack corr'lplex

[60,61]. K. pneumoniae strains that express low amounts of CPS can caJse an
increase of complement activators which increases deposit of C3 and both
complement-mediated and opsonophagocytic killing [60].
1.3.4.3 Antimicrobial Peptide Defense
Antimicrobial peptides pose a threat to the survival of K. pneumon/ae
during infection and the CPS acts as a countermeasure that can limit
antimicrobial peptides interaction with the

bactE~rial

cell. The CPS mimics human

cells by expressing polysialic acids in the capsule causing K. pneumoniao to be
poorly immunogenic [62]. In vitro findings show that low concentrations of
antimicrobial peptides (APs) up-regulate transcription of CPS, increasing the
amount of capsule particulates shed by K. pneumoniae from its cell surfaGe [63].
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Additionally, free anionic CPS released from J( pneumoniae naturally at1racts AP
neutralizing the killing ability of APs [64].

1.3.4.4 CPS Cluster Organization
CPS gene clusters are found in a single chromosomal locus, which allows
the coordinate regulation of a large number of genes involved in the biosynthesis
and export of the CPS [65]. Sequenced Klebsiella strains have 8 genes (gaIF,
acid PPC, wzi, wza, wzb, wzc, gnd and ugd) that are highly conserved in the

CPS clusters [66]. The JUMPstart (for "just upstream of many polysaccharide
starts") [67] element is part of transcriptional antitermination of the CPS cluster
and is found upstream of the gene wzi. Genes wza, wzb and wzc are a common
translocation-surface assembly pathway for cell surface CPS [66]. The mgions
described above are called "Region 1" and encode for the proteins neceHsary for
translocation of the polysaccharide through the peri plasm and across the outer
membrane [68]. The region following these genes is serotype-specific and is
responsible for biosynthesis and polymerization of oligosaccharide repeating
units [68].

1.3.4.5 magA
The magA gene is located in the CPS cluster of K. pneumoniae of K1
serotype has been identified as a virulence gene, responsible for the
hypermucoviscosity phenotype. The magA gene has been reported with a high
prevalence of 98.1 % for K. pneumoniae isolates from patients with liver
abscesses [50]. The disruption of the magA gene has resulted in the complete
loss of resistance to serum and phagocytosis with greater than a 105-fold
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increase in LDso for mice [69]. More recent studies, indicate that magA is a good
tool for molecular typing rather than a major virulence determinant for K.
pneumoniae strains that cause liver abscesses [50]. MagA and rmpA have been
proposed as good markers for the rapid diagnosis of liver abscess [70,71].
1.4 Animal Models
The use of animal models aids our understanding of the pathogeresis of
infectious diseases, as well as, the development of therapeutics and vac:ines.
Given that K. pneumoniae is capable of coloni;~ing a wide-range of host niches
several surrogate animal models have been developed to study the path ::>genesis
of this bacterium. In vivo experiments involving K. pneumoniae in the mouse
model use a number of routes of infection: UTI, intramuscular, intravenous,
intraperitoneal, oral inoculation, intranasal, surgical intratracheal and/or rlonsurgical intratracheal infection [72-78]. In the mouse model, there are thn3e
models that have been used to study pulmonary infection and they are:
intranasal, surgical intratracheal and/or non-surgical intratracheal infecticn. All
three models are designed to inoculate the lung to model human respiratory
disease caused by both community-acquired pneumonia as well as nosocomial
(e.g. ventilator associated pneumonia disease). The lung possesses several
forms of innate defenses against invading organisms including physical barrier,
the ciliary clearance of mucus from the lungs, and the rapid epithelial cell
signaling of immunoprotection, such as the activation of resident alveolar
macrophages [79].

9

1.4.1 Intranasal Model
The in vivo intranasal route of infection

~s

used to target the lungs, which

K. pneumoniae readily colonizes and is found to disseminates to both thH liver
and the spleen following intranasal infection [7:2]. Infections established by
intranasal delivery using strain ATCC 43816 resulted in rapid fatal

disea~,e

of

mice with a mortality rate at 2 to 4 day and LDso values of 3.0 x 103 [72, BO].
Even though rapid morality occurs in the intranasal infection model, the lower
respiratory tract is only one of three sites the inoculum is able to infect. VI/hen the
inoculum is deposited in the nares, it is able to infect both the upper and lower
respiratory track along with the digestive track [81]. Although K. pneumoniae is
known to infect all of these three locations, the target organ when using the
intranasal infection model is the lungs [81].
1.4.2 Surgical Intratracheal Model
The benefit of the intratracheal model is the direct delivery of K.
pneumoniae to the lungs and the avoidance of the infection in the upper
respiratory track. The surgical method involves the an incision to the venl ral neck
skin to expose the trachea, injecting the bacterial suspension by needle through
the trachea, and then stitching up the incision [82]. The intratracheal infection
using strain ATCC 4386 closely mimics intranasal infection rapid mortalit~' rate
with similar LD50 values (2 x 103 ) in ICR strain mice [83]. However, this method is
supposed to enhance delivery specifically to the lungs, but the trauma caused by
surgery has the potential to initiate a secondary infection.
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1.4.3 Non-surgical Intratracheal Model
In our laboratory, we developed a non-surgical, intubation-mediated
intratracheal model (IMIT) for K. pneumoniae respiratory disease studies. This
method involves intubation of mice followed by injection of the inoculum ::Iirectly
into the lungs [84]. The non-surgical intratracheal model removes infection from
the upper respiratory track while also eliminating the trauma caused by tile
surgical method and mimics contaminated ventilation catheters of hospihls in the
US. This mode of infection ensures complete delivery of the inoculum to the
lungs to simulate bacterial pneumonia in humans. We have identified an LO so of
4.71 x 10 1 for K. pneumoniae ATCC 43816 by the IMIT model in BALB/c mice
[84] and 103.6 CFU in female C57BU6 mice (unpublished findings). This [MIT
model demonstrates a lung-specific infection model which mimics the
contaminated ventilation catheters which is the major mode of infection for
hospitals acquired K. pneumoniae pneumonia infections in the US.

1.5 Hypothesis
Capsule is an important virulence determinant for K. pneumoniae,
however, recent Next Generation Sequencing efforts conducted by our laboratory
failed to fully sequence the K2 CPS cluster from strain ATCC 43816, a commonly
used K. pneumoniae strain to study respiratory disease. We predicted that K2
CPS clusters would be highly conserved with previously sequenced K2 CPS
clusters, and that the sequence of the ATCC 43816 K2 CPS cluster would allow
us to preform subsequent studies to investigate the role of CPS in K.
pneumoniae virulence. We also aimed to

deve~op

11

a novel bioluminescen·: strain

of K. pneumoniae through stable chromosomal introduction of the lux
allowing for the monitoring of the disease process in cell infection

op~ron,

assay~.

and

living animals. Finally, combining the use of these new tools (CPS seque nce and
bioluminescent K. pneumonia e) , we intended to monitor the role of K.
pneumoniae CPS in in vivo studies.

12

CHAPTER II
MATERIALS AND METHODS
2.1 Bacterial Strains and Media
All bacteria were stored in -80°C as 25% glycerol stocks and cultllred in
Luria broth (LB; Lennox, 1955) overnight at 3rC with shaking at 200 rpr1 unless
otherwise stated. All Klebsiella strains were thl3n subcultured (1 :25, vol/vol) into
2.5 ml trypticase soy broth (dialyzed and chelated) (TSBDC; Brett et aI., 1997)
containing fresh monosodium glutamate (2.5 M MSG stock) at a 1:50
concentration and grown at 3rC for 3 hours unless otherwise noted. E. ';oli
strain DH10B was used for cloning and E. coli strain S17-1 was used for
conjugation with K. pneumoniae. When appropriate, antibiotics were used at the
following concentrations: kanamycin (Km: 25 IJg/ml) , gentamicin (Gm: 2C !-Ig/ml
for NTUH and ATCC, 1000 !-Ig/ml for MGH), carbenicillin (Cb: 100 !-Ig/ml) , and
zeocin (leo: 25 !-Ig/ml or 100 !-Ig/ml). Details of strains and plasm ids used in this
study are shown in Table 2.1.
2.2 Molecular Biology
2.2.1 PCR Reactions
PCR amplification of cloning fragments or for PCR sequencing of fragments
smaller than 4 Kb was performed with Phusion High-Fidelity DNA polymerase
using the following protocol: initial denaturation at 98°C for 30 seconds followed

13

Table 2.1
Bacterial Strains and Vectors
Strain

Genotype/descri~tion

Source

DH10B

Electrocompetent E. coli cloning
strain

Invitrogen

S17-1 A pir

E. coli strain for conjugation

[85]

ATCC 43816

K. pneumoniae

[86]

NTUH-K2044

K. pneumoniae

[9]

MGH 78578

K. pneumoniae

[72]

ATCC43816::pJM
W106 -galF

K. pneumoniae::pJMW106-gaIF

This Study

ATCC43816::pJM
W106 -uge

K. pneumoniae::pJMW106-uge

This Study

WKPOO1

K. pneumoniae::pKSVS2·-Kp ATCCThis Study
nif-P rpIU-lux-floxZeo

JSKPOO1

K. pneumoniae:: Kp A TCC-nifPrplU-lux

This Study

pJET1.2

Blunt cloning vector

Fermentas

pCR4

TOPO-TA Cloning vector for
sequencing

Invitrogen

pCR4-ga1F

TOPO-TA Cloning vector harboring
galF fragment

This Study

pCR4-uge

TOPO-TA Cloning vector harboring
uge fragment

This Study

pJMW106-gaIF

Suicide vector harboring galF
fragment

This Study

pJMW106-uge

Suicide vector harboring uge
fragment

This Study

Plasmid
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Table 2.1 continued
Bacterial Strains and Vectors
Plasmid

pSK

pBluescript SK (+)

Stratagene

pSK-~cap-leo

pBluescript SK (+) vector
harboring ~cap-le()

This Study

pSK-~cap

pBluescript SK (+) vector
harboring ~cap

This Study

pJMW106

Suicide vector

Unpublished lab
vector

pJMW1 06-~cap-leo

Suicide vector harboring
leo

~cap-

pJMW1 06-~cap

Suicide vector harboring

~cap

pGSVS

Suicide vector

This Study

pKSVS2

Suicide vector

This Stud'y

pKSVS2-Kp ATCC-nitPrpIU-lux-floxleo

Suicide vector harboring PrplUlux-floxleo

This Study

pKSVS2-Kp ATCC-nitPrplU-lux

Suicide vector harboring PrpIUlux

This Stud'(

pKSVS-ptoIC-ere

Suicide vector harboring PtolCere

This Stud:(

pKSVS-PtoIC-cre-gaIF

Suicide vector harboring PtolCere-galF

This Stud:(
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This Study
This Study

by 30 cycles based on the following: 98°C for 10 seconds, 68°C for 30 sE'conds
and 72°C for 60 seconds for 1-2 Kb fragment, '120 seconds for 2-4 Kb fragments
and the final extension of fragment at 72°C for 10 minutes. Long Range PCR
amplification was performed with Phusion High-Fidelity DNA polymerase for
fragments larger than 4 Kb. The following protocol is used for long-range PCRs:
initial denaturation at 98°C for 30 seconds followed by 30 cycles based 01 the
following: 98°C for 10 seconds, 68°C for 30 seeonds and 72°C for 300 sEconds
for 4-8 Kb fragment or 600 seconds for 20 Kb fragments, and the final ex:ension
of fragment at 72°C for 10 minutes. All primers used are listed in Table 2.2.

2.2.2 Bacterial Enumerations
Viable cell count was performed by serial dilution of the original sample in
PBS, plating aliquots of the dilutions in

triplicatE~

onto an LB plates and

thl~n

incubating at 37° for 8 hours or at room temperature for 24 hours. After
incubation, the colonies were enumerated and the number of viable cells was
calculated. Serial dilution was conducted in a 96 well plate using 6 fold sE!rial
dilutions in eight wells. A multichannel pipettor was subsequently used to replica
plate the samples on an LB agar plate for enumeration (Figure 2.1).

2.3 Sequencing Capsular Polysaccharide Cluster
Next Generation Sequencing (NGS) was performed on ATCC 43S 16
which yielded five contigs of DNA spanning the capsule cluster. The five contigs
were bridged using either genomic DNA captune or primer walking techniques.
Similar methods were used in order to close gaps in contig level sequenc ng
efforts and obtain complete genome sequence for KCTC 2242 (AN: CPO(2910),
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Table 2.2
Oligonucleotides
Primer Oligonucleotide Sequence (5' -~ 3')
Number
GCGAGCTCCAGGCGCAGCCGCTGGG(;CTGG
galF Sacl (+)
1
GCCACTC
GTTCTAGACCGGCCCAGATATCCGCCGACAG
galF Xbal (-)
2
CACGTAG
GCGAGCTCCGGGCTGCGCTTCTTTACAGTGT
uge Sacl (+)
3
ATGGTCCGTG
GCTCTAGAGTCCAGCACATCTCCCGGCTGGA
uge Xbal (-)
4
TCGGCATCATATTCTTCTG
43816cap8-1 (+) GCTTCCAGCTCGTAGGAGGTGTCGAAGTGG
5
AAn-AAATCGCGGGCGCTAAAGCTG
43816cap8-2 (-) ACAGCAT
6
AAGTCG
GTGATGGTTTCCTGTAGCATGGAGTTCTGCCC
7
43816cap4-1 (+) G
CAGTTCCTGCAAAAGATCACTGATGCTfATGC
43816cap4-2 (-) GCAAAACG
8
43816cap3-1 (-) TGGATCCGCGTATCGGCAACCATTATAACAAC
9
CCG
10
43816cap3-2 (+) GCGGGTGTAAACCTTGTCCGCCACATCTGC
11
43816cap3-3 (-) GGAATGGAAGCGCAGAAGAATATGATGCC
12
43816cap3-4 (+) GTTCTTCAACTCCCGCGTCGTGCG
CTTCAGCAATCAGCTGCATGTCACCATACTCA
13
43816cap5-1 (+) ATGCC
14
43816cap7-2 (-) ATGCTGATGACCGGCGAAAGCTACGACTGCG
43816wzi (+)
CCAACGTCATCGCTGTCGCTGTTGTTA3CG
15
TCGACATGGCCGCTAAGCCAGGAAGAGATCG
16
43816wzi (-)
GCGACAATACACCTGTATCTTTTCCAG--ATCT
17
43816 wzc (+)
GCGACAG
TA
TTAATGGGGAGTCGCATTGAAAAGTfCCTT
18
43816 wzc (-)
GAGTGGGC
19
43816cap7-3 (+) GTACAACTGGGCTGGAGCGGTGACG
20
43816cap7-4 (+) ATCACCCGGAGCTGACAACACCTGC
21
43816cap7-5 (+) GGCAATGCTGAAGGTATGTCGCAAGCG
22
43816cap7-6 (+) CAACATTGCACCCGAAGCACGAGG
23
43816cap7-7 (+) GGGCAAGGTT,AAGTGGAGAGCACCAG 3G
24
43816cap7-8 (-) GAGTCTCAGGCATTGTTGCAACACGC
43816cap7-9 (-) GCAAGATCCGCAGGATTTTCTGTAGCAAGTAA
25
AAAGAAGGCGCCAAATTCCGCGAAAGTATTAA
26
galF-wzi (+)
AAAACTGC
I
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Table 2.2 continued
Oligonucleotides
Primer
Oligonucleotide
Number

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

43816wza-wzc( +)
wzi-wzc (+)
43816wzi-wza (+)
43816wzi2 (-)
Chedid ort 9 (+)
Chedid ort 9 (-)
43816wzx (+)
43816wzx (-)
43816Cap6-3 (+)
43816Cap6-4 (+)
43816Cap6-5 (+)
43816cap5-3 (-)
43816cap5-4 (-)
43816cap5-5 (-)
43816cap5-6 (-)
43816cap5-7 (-)
43816cap5-8 (-)
43816cap5-9 (-)
43816cap5-10 (-)
43816cap5-11 (-)
43816cap5-12 (-)
43816cap5-13 (+)
43816cap5-14 (+)
43816cap5-15 (-)
43816cap5-16 (-)

Sequence (5'

-~

3')

CAGCGACGCTACCGCCCCTGGC
GTGTCTGACCAAACCCCTGCGGAGTGC
CGCGTATIACACCAGCGCCTGTCTGC C
CGTCATCGCTGTCGCTGTIGTIAGC
GTTICAACTGATIGCCCATATCCTGCC
GCAAATAGCACTICGTCATIGG
CTATCTCGTATTCTGGAGCCATTIGAATTCGG
TGTITIGTC
GACGAAATAAGCCTTICATCTCAGCNl.GTAAC
TIATIAGGGC
ACTATGAGTATAAATGTGCTGTAGATGCAGG
CATCTAATAN~TICAGGAAAAGCGATATGG

CGATIGCGGTATCATIATGGTCGC
GTGGTCACTGCGACACGTICGCAGC
GCGCAAGGTIACGCCCCATCACAGCC
CGGACATCTGACCAAAAAGTACGTINAGAA
CTGCGG
CCTCAAACCCTAACCAAGGCTGC
GGAAGCATTIGCATICGAGCG
CGTGATIAACATTIGACAACCCG
CGCGCCTGGAGTGAAACACCATC
CAGTATAACTCCGATIATCAGCAAAC
GAGGTAAGCATICGTIGTGTGCCGC
GCTICTIGGCCACTAATAAAAACACACTCACC
CGCTCGGTATTGCTGGCCATGAGGC
CGTIAGTACAAGCATIGGAAGTGAGGGCACT
GGAAC
GACAAAACACCGAATICAAATGGCTCCAG
CCCCTTGTTGCCACGGATGAATATGTGTCTAT
ATCACTTGCAAGTGC
GAGAATICGTGAAAAACAATCAGCGG1TTGG
galF EcoRI (+)
TCAGGGTG
galf Xhol (-)
ATCTCGAGTCCTGCGACCGGAATAACCGC
CCCTCGAGCTGTTIGGTAACGATIAATTCTGC
ugd Xhol (+)
CTG
ugd Kpnl (-)
ACGGTACCGCTGTATGACCTGGTGGG C
GAAGAATTCCGCGCCGGGACGGTCCATCTIG
5' Kpin2 EcoRI(+) TTGACGAAGGCCAGCC
18

Table 2.2 continued
Oligonucleotides
Primer
Oligonucleotide Sequence (5' ~ 3')
Number
CAGCAGCGTATCCAGCAGGCCGGGAA~CGG
5' Kpin2 Nhel(-)
57
int1
GCGTCCAGGTCTTCCCG
GTCGGTACCGTGATTTATGGCGTGTTTGAAGG
3' Kpin2 Kpnl(-)
58
new
CGAGGG
3' Kpin2 Nhel(+) GCGGCTAGCCCTGACCCGGCCTACGG~GGC
59
new2
CGCCCGTCAGCTTATGTCC
60

floxZeo BspEI(+)

61

floxZeo Notl(-)

CTTCCGGATGGCTCGAGTTTTTCAGCAAGATG
TCCGGATCATAACTTCG
GATCTTCTAGAAAGATGCGGCCGCCAT~CTT

CG
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Figure 2.1

#2

Plating Scheme for Bacterial Enumerations
To enumerate bacteria, samples were diluted through serial dilutions on a 96 well
plate, and a row of eight samples was replica plated in 10 IJI aliquots on an LB
agar plate. The spots were plated in oval shape to avoid merging of independent
spots.
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NTUH-K2044 (AN: AB198423), and MGH 78578 (AN: CP000647).

2.3.1 Genomic Capture
The genomic capture process was performed by using insertional
mutagenesis to insert the vector pJMW106 into the gafF and uge genes located
in or near the capsule cluster. Approximately 400 bp fragments containir g
portions of the genes gafF and uge were PCR amplified using primer pairs 1/2
and 3/4 (Table 2.2). Each fragment was cloned into pCR4 vector generating the
vectors pCR4-ga/f and pCR4-uge respectively. The gafF and uge fragmE!nts were
then cloned into the pJMW106 vector using the Sacl/Xbal restriction sites to
generate the plasmids pJMW106-gafF and pJMW106-uge respectively. 817-1
was used to conjugate the pJMW1 06-gafF and pJMW1 06-uge

construct~,

into K.

pneumoniae ATCC 43816 and integration of the constructs were selecte j on

carbenicillin and kanamycin LB plates. Insertions were confirmed by

pcn and

named ATCC43816::pJMW106-gafF and ATCC43816::pJMW106-uge,
respectively.
ATCC43816::pJMW106-gafF and ATCC43816::pJMW106-uge genomic

DNA was isolated using the Promega Wizard Genomic DNA purification Kit.
Genomic DNA was digested using one of the following enzymes: EcoRI, Spel,
Notl or Sac!. The digested genomic DNA was then ligated and electroporated
into DH 1OB and grown on Km25 plates. Single colonies were chosen and grown
in LB broth containing kanamycin at 3rC with shaking. Plasmid DNA was
isolated by miniprep and digested using an appropriate restriction enzyme (listed
above). The digestion mixture was then placed into agarose gel for gel
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electrophoresis to show fragment captured along with the pJMW106 vector.
Sequencing efforts were conducted to characterize the captured chrome somal
fragments.

2.3.2 Primer Walking
PCR was used to close gaps between contigs that were missing from the
NGS of ATCC 43816 genome. Long range PCR was used to acquire template to
be used for primer walking. The first step was to extend the boundary of known
sequence into the unknown region of template by using PCR base primer
extension. Primers were then designed based off of the newly acquired
sequence and used to extend boundary of known sequence into unknown region
in an iterative process. All oligonucleotides used are listed in Table 2.

2.3.3 Sequencing of CPS Cluster
NGS returned five contigs of DNA spanning the capsule cluster IElaving 4
gaps to close. Using ATCC 43816 genomic DNA, a 1.2 Kb fragment was PCR
amplified and sequenced using primer pair 5/6 (Table 2.2 and Figure 2.2) to
sequence the gap adjacent to gene gafF. Subsequently, a 673-bp fragment was
PCR amplified and sequenced using primer pair 7/8 (Table 2.2 and Figure 2.2) to
sequence the gap between genes gnd and manG. A 1.5-Kb fragment was PCR
amplified using primer pair 9/10 (Table 2.2 and Figure 2.2) for template to
sequence the region from genes ugd to uge. Primers 9, 10, 11, and 12 (Table 2.2
and Figure 2.2) were used to sequence the 1.5-Kb fragment connecting
sequence of genes ugd and uge.
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Using long range PCR, a 20-Kb fragment was amplified using the primer
pair 13/14 (Table 2.2 and Figure 2.2). This 20-Kb fragment was used for template
to sequence remaining region between genes gafF and gnd. Primers were
designed based off Chedid and NTUH-K2044 sequence and the following two
primer pairs 15/16 and 17/18 (Table 2.2 and Figure 2.2) were used to acquire
two sequencing islands at 5' end of CPS cluster. This gave us two sequEmcing
gaps between genes gafF and wzc and using the primer walking technique made
use of primers 19-30 to complete closing of the gap (Table 2.2 and Figure 2.2).
Primers were designed based off Chedid sequence, and the two primer
pairs 31/32 and 33/34 (Table 2.2 and Figure 2.2) were used to acquire two
sequencing islands in the central region of the CPS cluster. The remaining
sequence was acquired using the primer walking technique primers 35-51 (Table
2.2 and Figure 2.2). The sequence was then manually aligned in Microsoft 2010
Word.
2.4 CPS Cluster Annotations

The sequenced capsule cluster was analyzed using Acaclone pDraw32
DNA analysis software to predict open reading frames (ORFs) encoding for
putative proteins greater than 35 amino acids. Homology searches of pu1ative
proteins predicted by pDraw32 were conducted using BLASTP Genbank (NCBI)
database. The gene name, description, and probable function of each pmdicted
gene was assigned according to the results of BLASTP (identity 70% and results
of BLASTP (identity 70% and matched length 80%) against NCBI K. pne,lmoniae
strains. The BLAST andlor CiusterW2 algorithm was used to compare

23

thl~

I~

~
~
~
~
~
~

~

~
~

:::t

24

I

~

~

homology of putative proteins identified by pOraw32 to all published K.
pneumoniae sequenced CPS clusters as of 12/1/12. The K. pneumoniae strains

used with accession number (AN) were: serotype K1 (NTUH-K2044 AN:
AP006725 and OTS AN: AY762939), K2 (CHEOIO AN: 021242 and VGI-I-535
AN: AB371296), K5 (NTUH-K9534 AN: AB289646 and VGH404 AN: AB371292),
K9 (VGH484 AN: AB371293), K14 (VGH916 AN: 371294), K20 (NTUH-KP13
AN: AB289648 and 889/50 AN: AB289647), K52 (MGH 78578 AN: CPO(0647),
K54 (NTUH-KP35 AN: AB289650) K57 (A1142 AN: AB334776), K62 (VGH698
AN: AB371295), non-typeable (NT) strain (A1517 AN: AB334777) and not
determined (NO) serotypes (NK29 AN: AB371290, NK8 AN: AB371289, NK245
AN: AB371291, KCTC 2242 AN: CP002910, HS11286 AN: CP003200,

~~p13

AN:

377737, and 1084 AN: CP003785).

2.5 Mutagenesis and Construction of the K. pneumoniae Capsule CI uster
Acap Mutant
Allelic exchange mutagenesis was performed in K. pneumoniae A TCC
43816 using the vector pJMW1 06. 1-Kb fragment containing a portion of the
gene gafF was PCR amplified using the primer pair 52/53 (Table 2.2) to make a
1-Kb fragment containing a portion of the gene a ugd was PCR amplified using
primer pair 54/55 (Table 2.2). The two fragments were cloned separately into
pJET1.2 and the two PCR fragments were then subsequently assembled
together using the common Xhol restriction site into the pSK vector creating the
vector

pSK-~cap.

A 500-bp fragment containing the zeocin antibiotic marker Sh

bfe gene was PCR amplified using primer pairs 60/61 (Table 2.2).The fra~ment
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was cloned into the common Xhol site between fragments gafF and ugd in the
vector pSK-Lkap creating vector pSK Llcap-Zeo. The assembled 2.5-Kb dcapZeo fragment was cloned into pJMW106 using EcoRl/Kpnl restrictions sites to
generate the allelic exchange plasmid pJMW106-dcap-Zeo. S17-1 was lIsed to
conjugate the pJMW106-dcap-Zeo construct into K. pneumoniae ATCC 43816
for the two-stage allelic exchange procedure, with the first stage

selectin'~

for

integration of the construct on LB agar plates containing carbenicillin and
kanamycin to isolate a merodiploid colonies. Single colonies were chosen and
grown in LB broth containing carbenicillin, kanamycin and zeocin. The second
stage of the allelic exchange procedure was done to select for the excision of the
vector from the genome while also removing the CPS cluster. 20 1-11 of LB broth
containing merodiploid colony grown in carbenicillin, kanamycin and zeoGin was
transferred to LB broth contain 15% sucrose and grown at room temperature
overnight. Subsequently, the next day 10 1-11 of LB broth was transferred to LB
agar plates containing 15% sucrose and grown at room temperature ovemight.
The following day single colonies were transferred to a LB agar plate containing
kanamycin followed by the transformation to an LB agar plate to confirm ':he loss
of the vector and the 25,000-bp fragment.

2.6 Infection of Cultured Macrophages
J774A.1 cells were maintained in DMEM (Gibco 11995) medium
supplemented with 10% heat-inactivated fetal bovine serum (HyClone) and
grown at 37°C with 5% CO 2 and 100% humidity. For infection studies,
monolayers of J774A.1 cells were seeded at a concentration of 7.5x104 cells per
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well (100 IJI) in a white 96-well plate (Greiner Bio-One) one day prior to illfection.
K. pneumoniae strains were grown as described above and bacterial
concentrations were estimated using spectrophotometry. The bacterial
suspensions were diluted in PBS to reach an MOl of 10,3 and 1 and 5 j.J1 aliquot
was inoculated into each well containing J774A.1 cells. One hour postinoculation, gentamicin was added to each well to kill the extracellular bctCteria.
At 3,4.5,6,9 and 12 hour post-inoculation, OM EM media was removed and 100
IJI of 0.1 % Trition was added to lyse cells. The solution was then transferred to 96
well U-bottom plate for bacterial enumeration (2.2.2).

2.7 Chromosomal Introduction of /uxCDABE Operon
We designed lux knock-in mutation using allelic exchange strategy to
insert the lux operon between genes fusA and yeeF. A 407 -bp fragment lNas
synthesized containing the stem loop terminator from the K. pneumoniae
genome and the promoter gene PrplUto regulate lux production. The two PCR
fragments from the K. pneumoniae genome [primer pair 57/58 (Table 2.2) and
59/60] were cloned separately into pSK at EcoRIIApal (1192-bp) and No·:IIKpnl
(1074-bp) fragments (Figure 2.3). The synthesized fragment was assembled
together with 5' fragment using the common BsiWI site engineered into both the
promoter and the 5' fragments were added to the pSK 5' Kpin2 vector. Tile two
fragments (5' Kpin2-PrplU and 3' Kpin2) were then assembled in pGSVS on
either end of the lux operon to yield pGSVS-Kpin-PrpIU-lux (Figure 2.3).
The zeocin antibiotic marker Sh ble gene was PCR amplified

usin!~

primers 60/61. The fragment was cloned into pSK creating the vector pSI<
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floxZeo. The floxZeo fragment was then cloned between 3' fragment and luxC
gene of the lux operon in the plasmid pGSVS-Kpin-PrpIU-lux. This created the
plasmid called pGSVS2-Kp ATCC-PrpIU-lux-floxZeo (Figure 2.3). The as:)embled
pGSVS2-Kp ATCC-PrpIU-lux-floxZeo plasmid was electroporated into S17-1 and
then conjugated into K. pneumoniae ATCC 43816 for a two-stage allelic
exchange procedure described above. The ATCC 43816::Kp ATCC-PrpIU-luxfloxZeo strain was named WKP001 (Figure 2.3).

2.8 Removal of Zeocin Antibiotic Marker from Strain WKP001
A 1-Kb fragment containing a portion of the gene galF was PCR amplified
using primer pairs 1/2 and inserted into pSK creating pSK-galF. The 1-Kb
fragment was then cloned into pKSVS-PtoIC-cre at Spel/Notl sites resulting in
the vector pKSVS-PtoIC-cre-galF. Strain WKP001 and S17-1 pKSVS-PtoIC-cregalF were grown separately in 4 ml of LB broth shaken overnight at 37°C. On the

following day, 1 ml of S17-1 pKSVS-PtoIC-cre-gaIFwas centrifuged for 1 minute
at 15,000g. The pellet was washed with 10 mM MgS04 and centrifuged

a,~ain.

The pellet was re-suspended in 100 IJL ofWKP001 LB overnight culture clnd then
transferred to a LB plate and grown at 3rC. Bacterial conjugation mixture was
streaked for single colony isolation on a Cb100/Km25 LB plate and grown at
3rC. Three single colonies were cultured overnight in 5 ml of LB broth with 15%

sucrose at 3rC with shaking. Subsequently, 10 IJI of the overnight culturE! was
streaked for single colonies on an LB plate and cultured at 3rC. The ten
colonies were replica plated on both Km25 and Cb100 LB plates. Colonie) which
were CbR/Kms were confirmed to be
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Figure 2.3
Chromosomal Introduction of luxCDABE Operon and Removal of leo Antibiotic
Marker
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also leo s in LB le0100 broth and the strain was named JSKP001 (Figu'e 2.3).

2.9 Investigation of the Light Production by Strain JSKP001
K. pneumoniae strain JSKP001 was grown overnight in LB in triplicate and
the cultures were subcultured in TSBDC broth in the 37°C incubator. Every 30
minutes for 4 hours, 100 IJI was taken from each triplicate and bioluminescent
measurements of plate were taken with Synergy HT plate reader (BioTel<,
Winooski, VT) (1 sec read, sensitivity of 135). Additionally, at each 30 minute
time point, 100 IJI was taken from each subculture processed for bacterial
enumerations as described above.

2.10 Chloramphenicol Spike of Strain JSKP001
Sub-lethal concentrations of chloramphenicol (150 IJg/ml ) were added 1
hour post-subculture to restrict new protein synthesis and subsequently restrict
bacterial growth. Chloramphenicol was added at a final concentration of 150
IJg/ml to JSKP001 cultures. Bacterial growth, bioluminescent measuremEmts, and
enumerations were performed as described above.

2.11 Infection of Cultured Cells with Bioluminescent Strain JSKPOO'I
J774A.1 cells were infected in a black 96-well plate using strain JSKP001
at an MOl of 10 to determine the correlation between bioluminescent readings
and bacterial numbers of K. pneumoniae. The luminescent measurements
(counts per second, cps) were taken with Synergy HT plate reader (BioTek,
Winooski, VT) immediately before harvesting samples for bacterial enumerations
at the 3, 4.5, 6, 9 and 12 hour post-infection time point, then immediately
bacterial enumeration was conducted as described above.
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2.12 Data Presentation and Statistical Analysis
Unless otherwise stated, Graph Pad Prism 5 was used to plot data and
conduct statistical analysis by unpaired Student's
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t-test.

CHAPTER III
RESULTS
GENOMIC ORGANIZATION OF K2 SEROTYPE K. PNEUMONIAE CPS
3.1 Introduction
K. pneumoniae ATCC 43816 is a representative K2 capsular serotype

strain that has been shown to be virulent in murine respiratory disease models.
Despite its relevance in the pathogenesis of respiratory disease, the genomic
sequence had not been previously determined. Therefore, our laboratory
performed Next Generation Sequencing (NGS) to acquire the sequence for the
complete genome of the ATCC 43816 strain. The NGS gave us an estimated

-80% coverage at the contig level based on previously sequenced genoilles of
other K. pneumoniae stains [84]. This coverage is comparable to other NGS
sequencing efforts [87, 88] and other historically used methods such as the
shotgun approach and genome fragmentation [9, 89]. However, only 22.-12%
sequence coverage of the CPS cluster was obtained from our NGS sequencing
efforts. Given this underrepresentation and the importance of the CPS cllJster for
virulence, we decided to manually sequence and assemble the remaindE!r of the
cluster. This type of gap closure is historically done by assembling contigs using
a large-insert library to determine orientation of contigs [9, 89], however, more
recently orientation is based on homology to previously sequenced strains and
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gaps are closed by sequencing PCR products [87, 88]. We used genom c
capture, primer walking and long-range PCR to close the gaps in the sequence
of the CPS cluster.

3.2 Genomic Capture
One approach we used to sequence the capsular polysaccharide cluster
was the genomic capture technique by using insertional mutagenesis of the
vectors pJMW106-gafF and pJMW106-uge, which flanked the CPS cluster
returned by NGS (Figure 3.1, yellow bars). Homologous portions of gafF and uge
genes were independently cloned into pJMW106, which is a non-replicating
vector in K. pneumoniae. The vectors were named pJMW106-gafF and
pJMW106-uge respectively and were conjugated into K. pneumoniae genome.

Growth in LB broth containing kanamycin was used to select for insertion of the
vector and the strains were named Kp ATCC::pJMW106-gafF and Kp
ATCC::pJMW106-uge. Purified genomic DNA of Kp ATCC::pJMW106-gcrfF and

Kp ATCC::pJMW106-uge was digested using a selection of enzymes available
that would retain the vector backbone and capture out a large portion of the
genomic DNA of the capsule cluster which was then ligated and amplified in E.

coli S17-1. Initial efforts did result in capture of genomic DNA, however, other
efforts described below yielded sequence more rapidly and, this technique was
discontinued.

3.3 Primer Walking and Long Range PCR
We used primer walking and long range PCR to sequence the remaining
regions of the capsular polysaccharide cluster. NGS returned five contigl; in the
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Figure 3.1
U

u..

"'iii
til)

~

....

0

1

I\gap l'

2
3
4

0..
0..
"U

·u
III

'N
~

III

.0

~

~

N

N

gap 2

U
N

~

,...

00

0"1

.-I

't:

't:

't:

't:

0

0

0

7
81

0

X

N

~

.-I

N

.-I

m

't:

't:

0

0

gap 3

I

~

5
6

0

•

-

......

III

'3

"U

~

I

I

gap 4'

U

co

E

1

C

C

ClI

"U

~

~

•

gap 51'

--

~-.,

Schematic Diagram of Sequencing Efforts of CPS the ATCC 43816 Cluster
w

.j::>

Scale representation of the CPS cluster illustrating the progression of closing sequencing gaps using genomic
capture and primer walking. The conserved CPS cluster (gafF to ugd) with gene identifiers indicated above each
open reading frame represented by blue arrows. Missing gaps named (1 , 2, 3, 4 and 5) in ascending order of the
direction of the ORFs. Row 1 (green bars) - contig level of NGS coverage; Row 2 (yellow bars) - sites for genomic
capture by insertional mutants; Row 3 (orange bars) - closure of gaps 1,4 and 5; Row 4 (Red bars) - sequence
obtained for genes wzi and wzc; Row 5 (blue bars) - finishing gaps 2; Row 6 (purple bars) - generating intermediate
islands with genes wzx and ORF 9; Row 7 (teal bars) - gap 3 completed; Row 8, summary of gap closure efforts to
sequence the CPS cluster.

CPS cluster (Figure 3.1, green bars) and the remaining unsequenced

re!~ion

was

broken up into five gaps. The small gaps 1, 4 and 5 were amplified by peR and
sequenced using genomic DNA, leaving one large gap located between genes
gafF and gnd (Figure 3.1, orange bars). Using long range PCR, a 20-Kb fragment

was amplified and served as the template for sequencing the remaining region of
the CPS cluster. Next, the sequence for the genes wzi and wze was obtclined
using primer walking technique with the 20-Kb fragment as template (Figure 3.1,
red bars) and provided two intermediate sequencing islands to extend

th~

sequence from the gafF gene. A 7-Kb gafF-wze fragment was amplified by PCR
and this fragment was used as a template to close the gaps in sequence
between gafF and wze (Figure 3.1, dark blue bar). The sequence from ORF 9 to
wzx was determined by using previously sequence K2 serotype K. pneumoniae

strains (Figure 3.1, pink bars) which providing two intermediate sequencing
islands to connect the sequence of genes wze to gnd (Figure 3.1, teal bar). This
completed the sequencing of the CPS cluster for the K2 serotype K. pnellmoniae
strain ATCC 43816.
3.4 GC content of K. pneumoniae ATCC 43816 K2 CPS cluster
We investigated the GC content of the CPS cluster of K. pneumoniae ATCC
43816 as this provides insight into the acquisition of the CPS cluster. ThE! CPS
gene cluster of ATCC 43816 is 23,804 bp in length and contains 18 open reading
frames (ORFs) from gafF to ugd (Figure 3.2). The average GC content of the
capsular polysaccharide cluster is 42.02%. Interestingly, we observed a central
region of seven genes, between gene wze and gnd, to have a much lower GC
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The CPS spans from gafF to ugd and the open reading frames are represented by arrows. A plot of the GC content
for the region using 30-bp sliding window is shown below the open reading frames . The red horizontal line represents
the mean GC content (59.53%) of the Next Generation Sequencing which covered -80% of the genome.

GC content of 31.8% (Figure 3.2 and Table 3.1). By comparison, both the
average CPS cluster and central region are well below the average GC content
of the entire ATCC 43816 genome (59.5%)[84]. This observation of low GC
content in the central region is consistent with 14 other K. pneumoniae CPS
serotype clusters [90]. This suggests that there is a recent acquisition of the
capsule cluster and perhaps rapid substitution of the core genetic element, which
may impact plasticity of capsular serotype.

3.5 Identification of K2-specific genes
We analyzed the sequence of the K2 CPS cluster of K. pneumoniae strain
ATCC 43816 against 23 other sequenced strains to identify the genes conserved
between the K2 serotype (Figure 3.3). The open reading frames (ORFs) of ATCC
43816 were annotated and given a probable function based on their alignment to
previously sequenced K. pneumoniae strains (Table 3.1). When additional
flanking sequence is available for sequenced K. pneumoniae CPS cluste rs, the
cluster is always located between genes yegH and uge. At the 5' end of the CPS
cluster there are six genes (gafF, acid PPC, wzi, wza, wzb and wzc) that are well
conserved among all K. pneumoniae strains and have been described aH a
common translocation-surface assembly pathway for cell surface CPS [66]. A
central region located between genes wzc and gnd appears to be the variable
region for the CPS clusters; however, a high homology is observed betwHen K.
pneumoniae strains containing the same serotypes suggesting the variable

region contains serotype specific genes (Figure 3.3). Amongst the sequenced K2
isolates (n=3), we observed high homology at both the genetic and amino acid
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Table 3.1

General Features of the 18 Genes Identified in ATCC 43816 CPS Gene Cluster

I I
O-ea lactase syn~sis

Membrane-associBted lipid
phosphatase
Polymerization and surface
assembly

eal F

UTP-eIUC02-1-phosphate
uridy ran~rase

Ac idpPC Aci d phosphate homoq

I

I I I I,
ea lF

59.1

298

100%

Kp (NTUH-K2044, K2,
NTUH- 9534, K9, K14,
K52, K6 2, NK245,Nk29,
1084)

Acl dPPC

58.6

209

99%

Kp(K2)

wzl

Outer membrane protein

wzi

54.2

477

99%

Kp(K2)

Polymerization and surface
assembly

wza

Mu lt i meric putative
transkxation channel

\vza

43,8

378

96%

Kp (K2, ( CTC 2242)

Polymerization and surface
assembly

wzb

Protei n tyrosine
phosphatase

wzb

36.3

144

97%

Kp (K2, CTC 2242)

Polymerization and surface
assembly

wzc

Inner membrane tyrosine
autokinase

wzc

35.6

686

97%

Kp (K2, ( CTC 2242)

Cata lV2ll! the transfer of suear

ori7

Group lelycosyl
transferase

o rf7

30.9

358

99%

Kp (K2, KCTC 2242)

Cata lV2ll!the transfer of suear

ori8

Group le1ycosyl
transferase

ori8

30.7

400

100%

Kp (K2, KCTC 2242)

orf9

Group le1ycosyl
transferase

orf9

30.1

286

96%

Kp(K2)

Cata lV2ll!the transfer of suear
Unknown
Polymer ationand surface
assembly
Unknown
Unknown

oril0 Hypotheti ca protein

orfl0

31.1

438

100%

wzx

Putative flippase w v(

W V(

31,9

485

99%

I<p (1<2)

orf 12

Hypothetical protein

ori12
ori 13

33.6
33,2

579

99%

192

98%

I<p (1<2, KCT(2242)
I<p (1<2, I<CTC 2242)

we aJ

35.1

465

99%

Kp (1<2, KCT(2242)

end

49.8

333

91%

Kp (1<1, K5, K9, K14, 1<54,
K62, 1<C"C2242, NI<29,
1084)
I<p (1<1, 1084)

ori13 Acetyltransferase

I<p (1<2, I<CTC 2242)

Undecapn!ny~ phosphate

UOP-elucase l ipid carrier
transferase

wcaJ

Unknown

end

e1ucose
phosphotransferase
Gl uconate-6-phospate
dehydroeenase

Synthesis of GOP-mannase
from mannose-&phosphate

manC

GOP-mannase
phosphorylase

manC

6 1.4

471

100%

Synthesis of mamose-lphosphate from mannose-&
phosphate

manS

Phosphomannomutase

manS

62.5

394

100%

SynthesisofUOP-elucuronic
ac id from UOP-e1ucase

ued

ued

50.6

388

100%

UOP-el ucase 6dehydroeenase

• ATCC 43816am ino-acid Ident ity percentaeeto species (serotype or stra'n) l isted in adjacent column.
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Kp(NTU~-K204~I<CTC

2242, NK245, 1084)

I<p(K9, CTC2242,
1084)

Figure 3.3
Jt2 : ATCC 43816
Jt2: Chedid (AN : 021242)
Jt2 : VGH525

NO : 1084

(AN : AB371296)

(AN : CP003785)*

1t5 :
1t5 : VGH404
K9 VGB484

(AN : AB371292)
(AN: AB371293)

Ki4: VGH916

(AN: AB371294)

Jt20 : NTOB-KP13

(AN: AB289648)

1t54: NTtJ8-KP35

(AN: 0289650)

1t57: Al142

(AN: AB334776)

K62 : VG8689

(AN: AB371295)

K62 : NTOB-KP53

(AN: AB290716)

NT : A1517

(AN : AB334777)

NO: Nlt245

(AN : AB371291)

NO: Nlt29 (AN: AB371290)
NO: NIt8
NO : Kp13

(AN : AB371289)
(AN: IN 377737)

NO : 8811286

(AN: CP003200)*
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Figure 3.3
Comparison of Sequenced K. pneumoniae CPS Clusters
The K. pneumoniae ATCC 43816 CPS gene clusters compared to the CPS loci
to ten K. pneumoniae serotypes (K1, K2, K5, K9, K14, K20, K52, K54,

K~i7,

and

K62), one new serotype (NT) and seven undetermined serotypes (NO). The
arrows with dotted lines belong to flanking genes of the CPS cluster. BluE! arrows
represent highly conserved genes present in all CPS regions. Orange arrows
correspond to genes of the highly conserved sequence, but presence and or
absence depends on serotype. ATCC 43816 K2 serotype genes with high
homology with other K2 serotype K. pneumoniae are represented by teal arrows.
Black arrows correspond to gene wzx, which are highly variable at the
level, but have an amino acid identity

~

se~uence

11 %. Red outline arrow represents

pseudogenes. In ATCC 43816, the suggested names for the ORFs are based on
amino-acid homology greater than 70%, with at least one annotated gene' from
another CPS region. For the previously published CPS regions, names indicated
above each gene correspond to annotations found in public databases, whereas
names in italic under the genes are suggestions based on pairwise comparisons.
* Re-annotation of NCBI data P: Promoter
Image adapted from Ferve, et al. [91]
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levels (Table 2). At the 3' end of the CPS cluster there are two genes (gnd and
ugd) highly conserved between all sequenced strains with the gene ugd which is

considered the last gene of the CPS cluster [91]. This data suggests that there is
both a conserved and variable region of the CPS cluster. The conserved is seen
in all serotype suggesting that the conserved genes are necessary for capsule
production, while the variable region is serotype specific.

3.6 Generating a capsular polysaccharide mutant
Capsular polysaccharide has been demonstrated to be a critical factor in
the virulence of K. pneumoniae in in vivo and in vitro models [72, 92]. Frcm this
sequence data, we intended to generate a capsule mutant strain which mmoved
the capsular polysaccharide from genes gafF to ugd. The development for the
capsule mutant was designed to create an in-frame mutant, which fused the gafF
start codon to the ugd stop codon deleting 23.7 -Kb of DNA. These two fragments
were assembled flanking the zeocin antibiotic marker (Sh bfe gene) containing
the foxP sites on either side. The foxP sites are recognized by Cre recombinase,
which catalyzes the recombination of DNA between two foxP sites. The
pJMW106-L\cap-floxZeo plasmid was then conjugated into K. pneumoniae ATCC
43816 for two-stage allelic exchange mutagenesis. During the conjugation, a
merodiploid K. pneumoniae strain was successfully generated; however, we had
R

difficulty in generating a Zeo clone that lacked the capsule cluster. Future efforts
will be required to identify whether essential genes are present within the CPS
cluster, whether other technical issues prevented the generation of this 2:3.7 Kb
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region of DNA or the development of smaller multiple gene mutant or sinl~le gene
mutant.
3.7 Conclusion
The CPS cluster investigated in this study has high homology to o'ther
sequenced K2 serotypes suggesting that genetic information could be used in
the future to predict serotype. The observation of a variable region located in the
central genes between wzc and gnd appears to be unique for each serotvpe.
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CHAPTER IV
RESULTS
J774A.1 MACROPHAGE INVOLVEMENT IN K. PNEUMONIAE INFECTIONS
4.1 Introduction
Successful bacterial pathogens must be capable of circumventing their
hosts' innate defenses, traffic to their preferred replicative niche and ultimately
persist within their hosts. K. pneumoniae is widely considered to be an
extracellular pathogen, though evidence for this characterization is circurlstantial
[93, 94]. However, recent studies have demonstrated its ability to be internalized
by epithelial cells and macrophages [47, 48, 61]. K. pneumoniae is know" to
cause a wide range of infections and is commonly isolated from the

lung~i.

Pulmonary infections have been shown to result in dissemination from thl:!
pulmonary airspace to the bloodstream. Alveolar macrophages reside in the
interphase between air and lung tissue and provide the first line of cellular
defense against microbes [95]. Previous research has demonstrated that alveolar
macrophages contribute to the defense against K. pneumoniae infection !n the
lungs [75]. Considering the fact that macrophages are the primary responders
against pneumonia, we decided to study the relationship between K. pner.Jmoniae
and J774A.1 murine macrophages.
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4.2 Internalization of K. pneumoniae
To investigate host-pathogen interaction of K. pneumoniae ATCC 43816,
NTUH-K2044 and MGH 78578 we infected J774A.1 murine macrophage
monolayers. To determine internalization of K. pneumoniae by J774A.1 cells, we
used gentamicin protection assays (1 hour post-infection). The cells werE!
challenged with an MOl of 10 for each strain of K. pneumoniae and 3 hours postinfection cells were lysed and enumerations were taken. The

macrophagl~s

were

observed to be viable by using immunofluorescence microscopy (data net
shown) and our results demonstrated that all three strains of K. pneumoniae
were able to be internalized by J774A.1 cells (Figure 4.1). For comparison, the
uptake efficiencies of all three strains were assessed by percentage of in,)culum
internalized by macrophage (i.e. survived gentamicin treatment by being
internalized by macrophages). We observed the internalization of strain MGH
78578 has the highest percentage inoculum uptake of 3.09%, with much lower
rates of uptake observed for both ATCC 43816 (0.57%) and NTUH-K2044
(0.17%). This data suggests that strain MGH 78578 is more readily phag()cytized
by macrophages when compared to strains ATCC 43816 and NTUH-K2044
(P<0.001, ***). These findings are consistent with the hypothesis that K.
pneumoniae is an extracellular pathogen which represses phagocytosis to
increase its virulence, as we have demonstrated that NTUH-K2044 and ATCC
43816 are virulent in our respiratory murine disease model, while MGH 7B578 is
relatively avirulent [84].
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Figure 4.1
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Internalization of Three K. pneumoniae Strains
Percentage of bacterial inoculum internalized by J774A.1 cells in four
independent (n=12) experiments represented by a whisker box plot. 7.5>:104
cells per well murine macrophages were infected with K. pneumoniae at an Mal
of 10 with strains ATCC 43816, NTUH-K2044, and MGH 78578. Gentam cin was
added one hour post-infection to kill extracellular bacteria and bacteria uptake
was assessed at 3 hours post-inoculation. Cells were lysed with 0.1 % Triton

x-

100 and enumerated by plate counting and percentage of inoculum was
calculated. Statistical analysis was carried out by one way ANOVA and Tukey
posttest (P<0.05, *; P<0.01, **; P<0.001 ;***) (Limit of detection 0.0013% of
inoculum).
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4.3 Proliferation of K. pneumoniae
We observed that K. pneumoniae strains could be internalized by J774A.1
macrophages at different levels, and we decided to investigate whether the three
K. pneumoniae strains exhibited different rates of proliferation within

macrophages. We infected replicate sets of J774A.1 cells with the three

,I(.

pneumoniae strains at an MOl of 10 and evaluated the ability of K. pneumoniae

to proliferate within J774A.1 cells with enumerations taken at 3, 4.5, 6, 9 and 12
hours post-infection. Our results show that all three strains can be internalized by
3 hours by the J774A.1 macrophage as similar numbers were observed (Figure
4.1 and Figure 4.2). However, both MGH 78578 and ATee 43816 showed an
initial decrease in bacterial numbers followed by proliferation over the course of
the infection (P<O.001, ***). The strain NTUH-K2044 was internalized as shown
previously, but exhibited little growth over the course of the experiment (No
significance). We also observed that ATee 43816 was taken up at a lowHr
bacterial number than MGH, however at later time points, ATee 43816
proliferated to similar bacterial numbers as MGH 78578. The low internalization
and proliferation of all three strains suggests that macrophages may not be the
preferred replicative niche for K. pneumoniae.
4.4 Conclusion
This work demonstrates that all three strains of K. pneumoniae can be
internalized and persist within macrophages for prolong periods of time. The
higher rate of internalization of the MGH 78578 strain could account for some
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Figure 4.2

2

****

i

-...
c:

Q)

o

: . ... . .... . .t:• . ~ w

•
•

ATCC MOl 10
NTUH MOl 10

•

MGH MOl 10

****

-1

.., • •

Q)

a..

i

-2

n.s .

---

•

-3

0

5

10

15

Time (hr)
Growth Curve of K. pneumoniae in Cultured Macrophage
Growth of internalized K. pneumoniae in J774A.1 cells over 12 hours. K.

pneumoniae strains ATCC 43816, NTUH-K2044, and MGH 78578 were used to
infect 7.5x1 04 cells per well in triplicate at an MOl of 10. After 1 hour, extracellular
bacteria were killed with gentamicin. At time points of 3,4.5 , 6, 9 and 12 hours
post-inoculation, samples were lysed with 0.1% Triton X-100 and enumerated by
plate counting. This figure is a representative of three independent trails with all
displaying similar results. The data is representative of at least three replicate
trials with plots of mean and standard error for each data point. Statistical
analysis was carried out by one way T-test (P<0 .05, *; P<0.01 , **; P<0.001 ;***,
P<0.0001 ;****) (Limit of detection 0.0013% of inoculum).
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lack of in vivo pathogenicity in the pulmonary infection model [84], whereas both
ATCC 43816 and NTUH-K2044 may control their internalization by phagocytes.
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CHAPTER V
RESULTS
ENGINEERING OF A LUMINESCENT K. PNEUMONIAE STRAIN
5.1 Introduction
Bioluminescence reporter systems have been engineered into many
species of bacteria to allow for the production of light to be used to monitor
disease processes in living systems [96-104]. The engineering of this bioreporter
into K. pneumoniae ATCC 43816 would enable us the ability to perform real-time
quantification of viable bacteria within a host. One of the most frequently used
bioluminescent reporter systems used in bacteria is the luxCDABE operon of

Photorhabdus luminescens which is a bacterial specific system with many
advantages over eukaryotic luciferases as the luxCDABE operon produces both
the luciferase enzyme and the substrates required for light production,
eliminating the need to provide substrate exogenously to the assay [105].
The single transcriptionalluxCDABE unit contains luxA and luxB genes
coding for the a- and r3-subunits that form a heterodimer luciferase [106]. The

luxCDE products work as a multienzyme fatty acid reductase complex required
for regeneration of the long-chain fatty aldehydes [105]. The long-chain fatty
aldehydes are subsequently oxidized by the luciferase heterodimer, with energy
supplied by flavin mononucleotide (FMNH 2 ), to produce a photon of blue/green
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light (-500nm)[1 05]. Unlike eukaryotic luciferases, bacterialluciferase system
requires no additional exogenous substrates to generate bioluminescence during
both in vitro and in vivo assays. This makes the lux operon an ideal system for
real time monitoring of bacteria.

5.2 Generating a /ux+ K. pneumoniae strain
ATCC 43816 strain is a well-studied K. pneumoniae strain, capable of
causing respiratory disease in animal models. We engineered the luxCDABE
operon into this strain for use in both in vitro and in vivo studies. The ATCC
43816 strain was engineered to produce constant, stable luminescence from the
luxCDABE operon and we used allelic exchange mutagenesis to insert the
operon into the chromosome. The insertion site of the lux operon was selected
based on the observation that a related Klebsiella strain possesses a nitrogen
fixation operon located between the arsenical resistance operon (fusA) and the
spore permease transport system (yeeF) which was found to be a conserved
region in other strains of K. pneumoniae (Figure 5.1). Therefore, this site was
selected for the insertion of the lux operon to minimize the impact on other
genetic systems or virulence. We cloned homologous portions of DNA to
facilitate allelic exchange including a portion of fusA and the neighboring
hypothetical gene (Figure 5.1, left side) and part of the yeeF (Figure 5.1, right
side). These two fragments were assembled to flank the lux operon in pGSVS
along with the rplU promoter, which was used to constitutively express the lux
operon. The rplU gene is a subunit of the 50S ribosomal subunit of protein L21
which catalysis mRNA-directed protein synthesis. We predicted that this
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Figure 5.1

fusA
Arsenical resistance operon

1Kb

spore permease
transport system

Schematic Diagram of the Genetic Organization of JSKP001
Scale representation of JSKP001 genetic organization . Nucleotide sequence of
the P. luminescens lux operon is given in GenBank (AN: M90093). lux operon is
flanked at the 5' end Gene fusA and a hypothetical gene (arsenical resistance
operon) and at the 3' end yeeF (spore permease transport system). The rplU
promoter was cloned upstream of the luxCDABE operon (purple rectangle) .
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ribosomal protein promoter will allow the lux operon to be constitutively
transcribed whenever the bacteria are metabolically active. The zeocin antibiotic
marker (Sh ble gene) was cloned at the end of the luxE gene with flanking 10xP
(flox) sites. These sites, known as the 10xP sequences, contain specific binding
sites for Cre that surrounds the two directional core 10xP sequences and allowing
for excision by recombination. The pGSVS2-Kp ATCC-PrpIU-lux-floXZeo plasmid
was then conjugated into K. pneumoniae ATCC 43816 for two-stage allelic
exchange mutagenesis, producing the luminescent strain WKP001. The removal
of the zeocin antibiotic marker was performed done by introducing the vector
pKSVS2-PtoIC-cre-gaIF into WKP001. Cre recombinase was transiently

expressed to excise the antibiotic marker, while leaving the PrplU-lux construct in
the chromosome. The sacB-marked Cre expression vector was selected against
using sucrose, and the resulting strain was named JSKP001.

5.3 In vitro bioluminescence of K. pneumoniae JSKP001
To investigate whether the light production from JSKP001 correlates with
bacterial numbers, we cultured JSKP001 in TSBDC broth media and examined
both light production and bacterial numbers at multiple time points. The bacteria
were grown with shaking in LB overnight and subcultured into TSBDC for four
hours (Figure 5.2A). TSBDC is a metal-depleted media which we routinely use to
mimic the metal-limited environment of the host. We observed statistically
significant exponential growth for the first three and a half hours of the broth
growth with evidence of stationary phase beginning at four hours. A trend line
was plotted through the first 3.5 hours of growth and we calculated a doubling

S2

time of 52.9 minutes. This doubling time is greatly reduced from K. pneumoniae
grown in LB which has a double time of 13 minutes [30], suggesting that the
metabolic state of the bacteria may be significantly different in LB and TSBDC.
During the time course of the TSBDC growth, we also measured
bioluminescence (counts per second (cps)) bacterial number's. The cps/CFU
ratio decreased after the first hour with statistically significant a decrease in light
emitted per bacteria over the course of the experiment. At three hours, the
bioluminescence resumed an altered correlation for the last hour (Figure 5.2A).
This suggests that JSKP001 grown in LB may have been more metabolically
active than in TSBDC and that a transition to an altered luminescent activity after
three hours growth in TSBDC reflects a change in the metabolic activity of the
bacteria. Alternatively, it is possible that the PrplU promoter may not be
constitutive in TSBDC.
Because the metabolic activity may impact the magnitude of light
production per bacteria, we hypothesized that altering the competition for energy
within the bacteria could impact light production. Therefore, we investigated how
arresting new protein synthesis with sub-lethal concentrations of chloramphenicol
[107] affects bioluminescence of JSKP001. We grew JSKP001 in LB overnight
and then subcultured into TSBDC, for one hour before adding chloramphenicol.
As expected, bacterial growth was repressed by chloramphenicol and bacterial
numbers remained unchanged throughout the experiment (Figure 5.2B). Unlike
previous trials in which we had a rapid decrease in the emitted light per bacteria
(Figure 5.2A), we observed that the cps/CFU dramatically increased in a
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K. pneumoniae strain JSKP001 was grown in TSBDC broth for 4 hours. Every 30 minutes, a 100 IJI volume was
drawn from the bacterial culture for a bioluminescent reading and bacterial enumeration . The exponential growth is
indicated with a trend line and used to determine doubling time (A) . In a separate experiment, chloramphenicol
antibiotic was added to the TSBDC broth 1 hour after initiating the experiment. A trend line was plotted to show
bacterial growth was repressed (B). Both experiments were performed in triplicate. Each data point is the mean
and standard error. Statistical analysis was carried out by one way T-test from the first to last data points of the
growth study (P<0.05, *; P<0.01, **; P<0.001 ;***). (Limit of detection 100 CFU of inoculum; Limit of detection 355
cps).

statistically significant manner after the addition of chloramphenicol (Figure
5.28). This level of light production remained high throughout the course of the
experiment and only began to decrease a later time points. This data suggests
that most energy-requiring bacterial proteins have relatively short half-lives which
break down and leave excess energy for the Lux proteins. Conversely, the data
suggests that the Lux proteins remain stable for the period of observation with
high level production of light for four hours. The elevated cps/CFU suggests that
typically the metabolic activity in bacterial cells leaves little energy available for
the luciferase activity. However, we hypothesize that blockage of protein
synthesis led to rapid turnover of many host proteins, decreasing the competitive
demand for energy of the relatively stable Lux proteins.

5.4 Intracellular Survival of /ux+ K. pneumoniae
We decided to evaluate the ability of K. pneumoniae strain JSKP001 to
produce light in a potentially important host-pathogen interaction model. To
investigate whether the light production from JSKP001 correlates with bacterial
numbers in an intracellular niche, JSKP001 was examined using our previous
gentamicin protection assay of cultured macrophages. We infected replicate sets
of J774A.1 cells with JSKPOO 1 at an MOl of 10 and bioluminescence was
measured by the plate reader immediately before harvesting the samples for
bacterial enumeration at 3, 4.5, 6, 9 and 12 hours post-infection (Figure 5.3). As
previously observed (Figure 4.1), approximately 0.7% of the K. pneumoniae
JSKP001 (ATCC 43816 derivant) inoculum was taken up by the J774A.1
macrophages, with statistically significant increase in bacterial numbers over the
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K. pneumoniae strain JSKP001 was used to infect murine J774A.1 cell line
(7.5x10 4 cells/well) in triplicate at an MOl of 10. After 1 hour, extracellular
bacteria were killed with gentamicin. At time points of 3,4.5,6,9 and 12 hour
post-inoculation, the light production of the sample sets as measured. The cells
were washed, then lysed using 0.1% T riton X-100, and the bacteria were
enumerated by plate counting. CFU/well was plotted as a function of time for
JSKP001. Bioluminescence was measured prior to cell lysing and cps/well was
plotted as a function of time. Each data point is the mean and standard error.
Statistical analysis was carried out by one way T -test comparing the first and last
data points (P<0.05, *; P<0.01 , **; P<0.001 ;***) (Limit of detection 0.0013% of
inoculum; Limit of detection 345 cps) .
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course of the experiment (Figure 5.3). Initially, the JSKP001 strain produced light
consistent with bacterial numbers, however after four and half hours the
luminescence per bacteria decreased in a statically significant manner over the
course of the experiment. These findings suggest that JSKP001 produces light
during host-pathogen interaction in the macrophage infection model; however,
the decrease in cps readings suggests that Lux proteins have a reduced
availability of energy for bacteria which persist in intracellular niches.
5.5 Conclusion
In this study, we developed a bioluminescent strain of K. pneumoniae by
engineering the luxCDABE operon into the chromosome. Lux proteins may be
more stable than other bacterial proteins, but appear to compete for the same
energy source as host bacterial proteins, with the potential for significant
variation in the availability of energy from one environment to another. Future
studies will be required to confirm by Western blot whether the Lux proteins
indeed possess longer half-lives than most host proteins. This study provided
evidence that K. pneumoniae might enter a dormant stage of reduced metabolic
activity when internalized by macrophages, or that the rplU promoter may be
significantly repressed within macrophages.
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CHAPTER VI

DISCUSSION
The CPS is one of the best characterized virulence factors of K.
pneumoniae as it facilitates resistance to complement-mediated bacteriolysis and
phagocytosis [48]. Studies have indicated that capsule-negative strains are
highly susceptible to rapid clearance in in vitro and in vivo assays which indicates
that CPS has a major impact on disease [61, 7'5, 92, 108]. Because the CPS of
K. pneumoniae is an important virulence factor, one of our objectives was to
completely sequence and preform bioinformatics analysis of the ATCC 43816
capsule biosynthetic cluster. Our results added to a growing list of genetically
characterized capsular clusters and revealed high sequence homology among
the K2 serotypes. Similar trends of high sequence homology are observed in four
additional serotypes that have multiple sequenced strains [91]. This information
suggests that if a sufficient number of sequenced and well characterized CPS
biosynthetic clusters were available, that genetic data could be used to predict
the serotype for Klebsiella. For example, the sequenced strain KCTC 2242 has
not yet been serotyped; however, the strain has high genetic homology to the
sequenced CPS clusters of K2 serotype and strongly suggests from genetics that
KCTC 2242 is a K2 serotype strain, which could be demonstrated in future
studies. Additionally, serotyping may encounter technical issues, as in the
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instance where serotyping efforts of the K. pn€,umoniae strain KpL 1 were not
previously successful in spite of the fact that it possesses the magA, gmd and
wcaG genes similar to the K1 capsular clusters [109].
Our data is adding to the growing set of evidence that every sequenced
strain from the Klebsiella genus has a highly conserved set of CPS genes
suggesting that capsule is a critical structure present in all Klebsiella. The
capsule biosynthetic cluster has 15 to 25 genes that are required for capsule
synthesis and of these, eight are conserved with high sequence homology
amongst K. pneumoniae subspecies pneumoniae, rhinoscleroma, oxytoca and K.
variicola [91]. Six of these genes cluster together in what appears to be a
transcriptional cluster at the 5' end of the CPS cluster and are involved in
polymerization control. They are thought to form a membrane pore through which
translocation of the CPS product is moved from the inner membrane to the cell
surface for capsule assay [110]. Single gene mutants within these genes lead to
acapsular phenotypes with loss of high-molecular weight extracellular polymer
with the accumulation of the CPS precursors in the periplasm of the bacteria
[111]. Two additional conserved genes (gnd and ugd) are located downstream of
the variable region of the CPS biosynthetic cluster. The gnd gene encoding an
NADP-dependent 6-phosphogluconate dehydrogenase is involved in the pentose
phosphate pathway which converts 6-phosphogluconate into ribulose 5phosphate and produces NADPH for reductive biosynthesis and nucleotide
biosynthesis [112]. The ugd gene encodes UDP-glucose dehydrogenase, which
converts UDP-glucose into UDP-glucuronic acid, the substrate for capsule
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synthesis [113]. The high degree of conservation of the core set of eight genes
amongst members of the Klebsiella genus suggests a common ancestry of these
genes and conserved mechanism of capsule assembly. Homologues of these
eight conserved genes are also found in a variety of intestinal flora bacteria, such
as Enterobacter aerogenes, Salmonella enterica, Escherichia coli, Serratia
marcescens and Shigella boydii and potentially amongst other members of the
Enterobacteriaceae family [114-118].

The genetic arrangement of the CPS cluster has a genetically variable
CPS locus which is thought to contribute to the diversity of the capsular
polysaccharide serotype of K. pneumoniae and is flanked by conserved genes.
Because of this conservation found within the Enterobacteriaceae family there
may be exchange of the CPS using homologous recombination in the intestine.
The intestine has been previously demonstrated to be a potential site for
interchange of genetic material as K. pneumoniae has been observed to transfer
antibiotic resistant genes to E. coli in the mouse intestine [119]. While
homologous recombination of large segments of the CPS cluster might happen
at very low frequency, there is evidence for horizontal gene transfer of capsule
genes amongst members of the Enterobacteriaceae family as observed by a high
genetic similarity of the capsule clusters of E. coli K30 and K. pneumoniae K20
suggesting recent exchange of CPS clusters between these two species [120,
121]. Additionally, the capsule of E. coli K42 was observed to have a
serologically identical capsule as a K. pneumoniae K63 strain [113, 122],
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supporting the evidence that members of the Enterobacteriaceae family may
exchange CPS gene clusters, potentially in the! intestine.
The CPS of K. pneumoniae may be one factor in directing host niche
specificity for different K. pneumoniae strains. It has been shown that multiple
serotypes infect different niches. For example, serotypes 21, 33 and 69 are
predominately found causing infections in the lJrinary tract, while serotypes 30
and 31 predominately are found causing wound infection [123]. However, of the
80 different serotypes identified, most reports indicate that K1 and K2 serotypes
are amongst the most common isolated from patients and additionally are the
most invasive strains [123-127]. It has been suggested that the degree of
virulence conferred by a particular K antigen of K. pneumoniae might be
connected to the man nose content of the CPS. Capsular types associated with
low virulence, such as the K7 or K21a antigen, contain sequences of mannose-a2/3-mannose or L-rhamnose-a-2/3-L-rhamnose which are recognized by a
surface lectin of macrophages [128-130]. Macrophages with the mannose-a-2/3mannose-specific lectin or man nose receptor recognize, ingest, and
subsequently kill K. pneumoniae CPS serotypes containing mannose. In
contrast, strains with theK2 serotype, which lack the man nose repeating
sequence, are not phagocytized [131]. Thus, K. pneumoniae CPS may play an
important role in directing the preferred host niGhe, in part mediated by
immunomodulation.
Macrophages are considered major effector cells of host defense against
respiratory tract infections by virtue of their potent phagocytic properties. In
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addition, macrophages may regulate the host inflammatory response to infection
by the production of cytokines [132]. Alveolar rnacrophages are important for the
rapid elimination of K. pneumoniae from respiratory tract and by orchestrating the
inflammatory response against this pathogen [133]. We analyzed the interplay
between K. pneumoniae strains and J774A.1 macrophage cells to get a better
understanding of the host response to K. pneumoniae infections. Our results
demonstrated that K. pneumoniae can be internalized by macrophages at low
levels and survive for prolonged periods of time. However, some strains of K.
pneumoniae may not proliferate in macrophages at high levels typically observed

for intracellular bacterial pathogens, which suggests K. pneumoniae may excel
as an extracellular pathogen. However, macrophages might be a potential niche
for chronic persistence in sublethal infections. There is clinical evidence that K.
pneumoniae is capable of causing chronic disease with frequent and recurrent

manifestation in the liver up to ten year post infection [134, 135]. Recurrent
infection is also seen in other bacteria such as Mycobacterium tuberculosis,
which colonize macrophages, enter a latent phase, and then causes a
subsequent acute disease [136].
We engineered a bioreporter into K. pneumoniae ATCC 43816 to enable
us the ability to perform real-time quantification of viable bacteria. While
investigating how light production from JSKP001 correlated to bacterial numbers,
we first observed that bacteria cultured in TSBDC had a relatively high level of
light emitted per bacteria (1.167 x 10-3 cps/CFU), but after about three hours, the
bacteria transitioned to a much reduced light emission per bacteria (1.713 x 10-6
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cps/CFU) (Figure 6.1A). This brought up several questions for us. Was the
transcriptional regulation of the rplU promoter Gausing reduced expression of Lux
proteins or was the efficiency of the enzymes negatively impacted by the
metabolic state of the bacteria? Because the metabolic activity may impact the
magnitude of light production per bacteria, we altered the competition for energy
within the bacteria by stopping new protein synthesis. We observed that the Lux
proteins were competing for the same energy source as host bacterial proteins
(ATP) (Figure 6.1), but also observed that the ILux proteins appear to have a
longer half-life than most host proteins and are! able to access additional energy
for light production in the absence of competition. When examining the products
needed for light production, ATP is used to regenerate long chain fatty aldehydes
and the TCA cycle to regenerate FMNH2 (Figure 6.1 B). Both products are
oxidized by the LuxAB dimer in the presence of oxygen to product light (Figure
6.1 B). Because the Lux proteins appear to be competing for the same energy
source there is a potential for variation in the availability of energy when K.
pneumoniae goes from one environment to another causing an alteration in

metabolism within the bacteria. We have not addressed the possibility that the
rplU promoter may not be constitutively expressed in macrophages which we

could investigate using RT-PCR studies.
An original aim of this thesis project was to bridge the two major aims by
developing a capsule mutant and use the luminescent tool to monitor disease
progression for the capsule mutant in the respiratory disease model. We were
unsuccessful in generating a capsule mutant, thus future experiments will identify
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Figure 6.1

A

Early TSBDC

Late TSBDC

TSBDCCm

~~
luxCDABE

1. 713 X 10.6 cps/CFU

B
Lone chain
Fatty aldehyde

Summation of Figure 5.2
Schematic diagram of K. pneumoniae cells in TSBDC during different time
points and with or without chloramphenicol. Blue wavy lines represent mRNA
transcript of the /uxCDABE operon . The red/orange circles represent relative
numbers of LuxAB protein dimer and purple shape represent relative numbers of
bacterial host proteins. ATP is represented at yellow stars and lime green around
cells is relative production of light produced by LuxAB proteins (A) . The
mechanism of light production is a complex series of energy requiring
oxidation/reduction reactions where the LuxAB protein dimer requires energy for
the production of light in the form of both ATP and NADH/NADPH from the TCA
cycle (B).
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whether essential genes are present within the CPS cluster or whether other
technical issues prevented the generation of this 23.7 Kb region of DNA. Future
studies will be needed to demonstrate that the transfer of capsule biosynthetic
clusters can be shared between the Enterobacteriaceae family. Additionally,
future studies will also be required to characterize the role of macrophages in
recurrent K. pneumoniae disease. We are also interested in examining whether
bioluminescence can be used to monitor disease progression in animal models.
Some of these future directions are already being performed within the lab as the
animal studies are currently on going in the laboratory and raise good evidence
that the there is a correlation between luminescence and bacterial numbers
within animal tissues.
In conclusion, we have genetically characterized the K2 serotype capsular
polysaccharide cluster from ATCC 43816. Comparative genomics indicate that
there are both conserved and variable regions within all sequenced capsular
polysaccharide cluster of K. pneumoniae which could provide exchange of the
serotype specific genes through the mechanism of horizontal gene transfer. Our
understanding from our macrophage studies that K. pneumoniae prefers to be an
extracellular pathogen as it enters a novel latent phase within the macrophages.
Furthermore, we validated a diagnostic imaging tool for K. pneumoniae to
support macrophage internalization studies and the tools developed in these
studies is currently being used to support animal respiratory disease model. Plus,
additional future studies will be needed to demonstrate that the transfer of
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capsule biosynthetic clusters can be shared between the Enterobacteriaceae
family.
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